Journal of Bone and Mineral Metabolism

, Volume 37, Issue 1, pp 72–80 | Cite as

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy

  • Seiichi KatoEmail author
  • Makoto Kawase
  • Daiki Kato
  • Takashi Ishida
  • Masahiro Uno
  • Yoshinori Fujimoto
  • Takako Masue
  • Naruyasu Masue
  • Takashi Deguchi
Original Article


The aim of this study was to conduct a cross-sectional survey of investigations related to the bone mineral density (BMD) of both non-metastatic prostate cancer (NMPC) patients who have not yet received androgen deprivation therapy (ADT) and patients receiving prolonged ADT in Japan. Japanese male patients with NMPC who received continuous ADT or who were planning to receive ADT were enrolled in this study. Lumbar spine and femoral neck BMD was measured using dual-energy X-ray absorptiometry (DEXA). To assess patient characteristics, we searched medical records and questionnaires to determine whether they had any factors that could possibly affect BMD. A total of 230 patients with a mean age of 76.6 ± 6.4 years were evaluated. Of these, 151 (65.7%) were receiving ADT, and 79 (34.4%) had not yet received ADT. The mean duration of ADT was 37.4 ± 30.7 months. DEXA showed that as the duration of ADT increased, lumbar spine and femoral neck BMD decreased gradually (p = 0.0005 and p = 0.0014, respectively). Stepwise regression analyses revealed that the duration of ADT was a significant variable of both lumbar spine and femoral neck BMD. Moreover, as the duration of ADT increased, the prevalence of osteoporosis increased statistically (p = 0.0002). This study showed that ADT negatively affected lumbar spine and femoral neck BMD. It also showed a progressive increase in the prevalence of osteoporosis in Japanese NMPC patients with ADT.


Asian Continental Ancestry Group Bone density Gonadotropin-releasing hormone Osteoporosis Prostatic neoplasms 



We thank the patients of Ogaki Municipal Hospital (Ogaki, Japan).

Compliance with ethical standards

Conflict of interest

All authors have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61CrossRefGoogle Scholar
  2. 2.
    Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504CrossRefGoogle Scholar
  3. 3.
    Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of multicenter phase 3 clinical study. J Urol 179:152–155CrossRefGoogle Scholar
  4. 4.
    Gilbert SM, McKiernan JM (2005) Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 15:23–27CrossRefGoogle Scholar
  5. 5.
    Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417CrossRefGoogle Scholar
  6. 6.
    ShahinianVB Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRefGoogle Scholar
  7. 7.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL (2005) Gonadotropin-releasing hormone agonisits and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897–7903CrossRefGoogle Scholar
  8. 8.
    Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007CrossRefGoogle Scholar
  9. 9.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at primary health-care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases, University of Sheffield, UKGoogle Scholar
  10. 10.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2005) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679–1683CrossRefGoogle Scholar
  11. 11.
    Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800–805CrossRefGoogle Scholar
  12. 12.
    Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186:482–486CrossRefGoogle Scholar
  13. 13.
    Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL (2011) Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 14:348–353CrossRefGoogle Scholar
  14. 14.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75:1131–1137CrossRefGoogle Scholar
  15. 15.
    Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449–452CrossRefGoogle Scholar
  16. 16.
    Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H (2004) Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64:128–131CrossRefGoogle Scholar
  17. 17.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. Cancer 115:3468–3474CrossRefGoogle Scholar
  18. 18.
    Israeli RS, Ryan CW, Jung L (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179:414–423CrossRefGoogle Scholar
  19. 19.
    Lloyd JT, Alley DE, Hawkes WG, Hochberg MC, Waldstein SR, Orwig DL (2014) Body mass index is positively associated with bone mineral density in US older adults. Arch Osteoporos 9:175. CrossRefGoogle Scholar
  20. 20.
    Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, Mcclung M, Hosking D, Yates AJ, Christiansen C (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622–1627CrossRefGoogle Scholar
  21. 21.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122–126CrossRefGoogle Scholar
  22. 22.
    Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes−a meta-analysis. Osteoporos Int 18:427–444CrossRefGoogle Scholar
  23. 23.
    Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED (2017) Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 119:239–244CrossRefGoogle Scholar
  24. 24.
    Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91:2238–2245CrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyOgaki Municipal HospitalOgakiJapan
  2. 2.Masue ClinicGifuJapan
  3. 3.Department of UrologyGifu University School of MedicineGifuJapan

Personalised recommendations